Going Global Gets Stuck, Chinese Drug Makers CRL Show What Not To Do
Holistic not opportunistic approach required
Chinese drug makers have more to lament and plenty to learn from as Junshi, HutchMed follow Innovent Bio with FDA rejections. A holistic not opportunistic approach is needed, one ex-FDA expert suggests.
